{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:03:05Z","timestamp":1788814985862,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40257-024-00902-y","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:01:42Z","timestamp":1731456102000},"page":"61-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus"],"prefix":"10.1007","volume":"26","author":[{"given":"Nikolai Dario","family":"Rothermel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-5935","authenticated-orcid":false,"given":"Carolina","family":"Vera Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-1360","authenticated-orcid":false,"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3450-0877","authenticated-orcid":false,"given":"Jie Shen","family":"Fok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-0372","authenticated-orcid":false,"given":"Leonie Shirin","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-0959","authenticated-orcid":false,"given":"Emek","family":"Kocat\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5967-4809","authenticated-orcid":false,"given":"Sophia","family":"Neisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5649-2698","authenticated-orcid":false,"given":"Manuel P.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-083X","authenticated-orcid":false,"given":"Indrashis","family":"Podder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-2900","authenticated-orcid":false,"given":"Polina","family":"Pyatilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9289-5960","authenticated-orcid":false,"given":"Aiste","family":"Ramanauskaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-4502","authenticated-orcid":false,"given":"Melba","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-9654","authenticated-orcid":false,"given":"Karoline","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-481X","authenticated-orcid":false,"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3567-0149","authenticated-orcid":false,"given":"Hanna","family":"Bonnekoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5380-8132","authenticated-orcid":false,"given":"Pavel","family":"Kolkhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"11","key":"902_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.mayocp.2014.04.015","volume":"89","author":"A Arora","year":"2014","unstructured":"Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MD, Lohse CM. Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2014;89(11):1515\u201324. https:\/\/doi.org\/10.1016\/j.mayocp.2014.04.015.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"902_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaci.2018.09.007","volume":"143","author":"P Kolkhir","year":"2019","unstructured":"Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: s systematic review. J Allergy Clin Immunol. 2019;143(2):458\u201366. https:\/\/doi.org\/10.1016\/j.jaci.2018.09.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"902_CR3","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.jaip.2022.07.003","volume":"10","author":"H Bonnekoh","year":"2022","unstructured":"Bonnekoh H, Jelden-Thurm J, Butze M, Krause K, Maurer M, Kolkhir P. In urticarial vasculitis, long disease duration, high symptom burden, and high need for therapy are linked to low patient-reported quality of life. J Allergy Clin Immunol Pract. 2022;10(10):2734-41.e7. https:\/\/doi.org\/10.1016\/j.jaip.2022.07.003.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"902_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jaci.2013.04.008","volume":"132","author":"K Krause","year":"2013","unstructured":"Krause K, Mahamed A, Weller K, Metz M, Zuberbier T, Maurer M. Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J Allergy Clin Immunol. 2013;132(3):751-4.e5. https:\/\/doi.org\/10.1016\/j.jaci.2013.04.008.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"902_CR5","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.jaip.2023.06.030","volume":"11","author":"H Bonnekoh","year":"2023","unstructured":"Bonnekoh H, Jelden-Thurm J, Allenova A, Chen Y, Cherrez-Ojeda I, Danilycheva I, et al. Urticarial vasculitis differs from chronic spontaneous urticaria in time to diagnosis, clinical presentation, and need for anti-inflammatory treatment: an international prospective UCARE study. J Allergy Clin Immunol Pract. 2023;11(9):2900-10.e21. https:\/\/doi.org\/10.1016\/j.jaip.2023.06.030.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"902_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12305","volume":"13","author":"K Krause","year":"2023","unstructured":"Krause K, Bonnekoh H, Jelden-Thurm J, Asero R, Gimenez-Arnau AM, Cardoso JC, et al. Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: an international Delphi survey. Clin Transl Allergy. 2023;13(10): e12305. https:\/\/doi.org\/10.1002\/clt2.12305.","journal-title":"Clin Transl Allergy."},{"issue":"2","key":"902_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/09546630802314670","volume":"20","author":"S Kausar","year":"2009","unstructured":"Kausar S, Yalamanchili A. Management of haemorrhagic bullous lesions in Henoch-Schonlein purpura: is there any consensus? J Dermatol Treat. 2009;20(2):88\u201390. https:\/\/doi.org\/10.1080\/09546630802314670.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"902_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clindermatol.2016.09.013","volume":"35","author":"J Kazandjieva","year":"2017","unstructured":"Kazandjieva J, Antonov D, Kamarashev J, Tsankov N. Acrally distributed dermatoses: vascular dermatoses (purpura and vasculitis). Clin Dermatol. 2017;35(1):68\u201380. https:\/\/doi.org\/10.1016\/j.clindermatol.2016.09.013.","journal-title":"Clin Dermatol"},{"issue":"6","key":"902_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/dth.12103","volume":"26","author":"AN Mathur","year":"2013","unstructured":"Mathur AN, Mathes EF. Urticaria mimickers in children. Dermatol Ther. 2013;26(6):467\u201375. https:\/\/doi.org\/10.1111\/dth.12103.","journal-title":"Dermatol Ther"},{"issue":"4","key":"902_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jaci.2022.02.007","volume":"149","author":"AV Marzano","year":"2022","unstructured":"Marzano AV, Maronese CA, Genovese G, Ferrucci S, Moltrasio C, Asero R, et al. Urticarial vasculitis: clinical and laboratory findings with a particular emphasis on differential diagnosis. J Allergy Clin Immunol. 2022;149(4):1137\u201349. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"902_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-023-00665-y","volume":"24","author":"X Xiao","year":"2023","unstructured":"Xiao X, Xue P, Shi Y, Yao J, Cao W, Zhang L, et al. The efficacy and safety of high-dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized clinical trials. BMC Pharmacol Toxicol. 2023;24(1):23. https:\/\/doi.org\/10.1186\/s40360-023-00665-y.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"902_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.reprotox.2008.05.053","volume":"26","author":"C Weber-Schoendorfer","year":"2008","unstructured":"Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy: a prospective observational cohort study. Reprod Toxicol. 2008;26(1):19\u201323. https:\/\/doi.org\/10.1016\/j.reprotox.2008.05.053.","journal-title":"Reprod Toxicol"},{"issue":"9","key":"902_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2165\/00002018-200831090-00006","volume":"31","author":"EB Schwarz","year":"2008","unstructured":"Schwarz EB, Moretti ME, Nayak S, Koren G. Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis. Drug Saf. 2008;31(9):775\u201388. https:\/\/doi.org\/10.2165\/00002018-200831090-00006.","journal-title":"Drug Saf"},{"key":"902_CR14","unstructured":"US FDA. Highlights of prescribing information: Xolair\u00ae (omalizumab) injection, for subcutaneous use. Initial U.S. approval: 2003. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103976s5245lbl.pdf. [Accessed 17 Apr 2024]."},{"issue":"8","key":"902_CR15","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","volume":"11","author":"KW Chuang","year":"2023","unstructured":"Chuang KW, Hsu CY, Huang SW, Chang HC. Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2023;11(8):2382-9.e3. https:\/\/doi.org\/10.1016\/j.jaip.2023.05.033.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"902_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/jaa.S363398","volume":"15","author":"F Menzella","year":"2022","unstructured":"Menzella F, Fontana M, Contoli M, Ruggiero P, Galeone C, Capobelli S, et al. Efficacy and safety of omalizumab treatment over a 16-year follow-up: when a clinical trial meets real-life. J Asthma Allergy. 2022;15:505\u201315. https:\/\/doi.org\/10.2147\/jaa.S363398.","journal-title":"J Asthma Allergy."},{"key":"902_CR17","doi-asserted-by":"publisher","first-page":"8191","DOI":"10.1038\/srep08191","volume":"5","author":"T Lai","year":"2015","unstructured":"Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191. https:\/\/doi.org\/10.1038\/srep08191.","journal-title":"Sci Rep"},{"issue":"1","key":"902_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaip.2019.07.021","volume":"8","author":"M T\u00fcrk","year":"2020","unstructured":"T\u00fcrk M, Carneiro-Le\u00e3o L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113\u201324. https:\/\/doi.org\/10.1016\/j.jaip.2019.07.021.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"902_CR19","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1136\/annrheumdis-2019-215605","volume":"78","author":"T Bettuzzi","year":"2019","unstructured":"Bettuzzi T, Deroux A, Jachiet M, Farhat MM, Wipff J, Fabre M, et al. Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: a French multicentre retrospective study. Ann Rheum Dis. 2019;78(10):1446\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215605.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"902_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/03009740600938647","volume":"36","author":"C Botsios","year":"2007","unstructured":"Botsios C, Sfriso P, Punzi L, Todesco S. Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra. Scand J Rheumatol. 2007;36(3):236\u20137. https:\/\/doi.org\/10.1080\/03009740600938647.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"902_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/art.38956","volume":"67","author":"M Jachiet","year":"2015","unstructured":"Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015;67(2):527\u201334. https:\/\/doi.org\/10.1002\/art.38956.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"902_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.revmed.2017.03.005","volume":"39","author":"M Jachiet","year":"2018","unstructured":"Jachiet M, Flageul B, Bouaziz JD, Bagot M, Terrier B. Hypocomplementemic urticarial vasculitis. Rev M\u00e9d Interne. 2018;39(2):90\u20138. https:\/\/doi.org\/10.1016\/j.revmed.2017.03.005.","journal-title":"Rev M\u00e9d Interne."},{"issue":"4","key":"902_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab: a critical care perspective. Crit Care. 2012;16(4):231. https:\/\/doi.org\/10.1186\/cc11304.","journal-title":"Crit Care"},{"issue":"3","key":"902_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"issue":"11","key":"902_CR25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11489","volume":"12","author":"A Satapathy","year":"2020","unstructured":"Satapathy A, Biswal B, Priyadarshini L, Sirka C, Das L, Mishra P, et al. Clinicopathological profile and outcome of childhood urticaria vasculitis: an observational study. Cureus. 2020;12(11): e11489. https:\/\/doi.org\/10.7759\/cureus.11489.","journal-title":"Cureus."},{"issue":"6","key":"902_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2500\/aap.2016.37.3999","volume":"37","author":"D Ledford","year":"2016","unstructured":"Ledford D, Broder MS, Antonova E, Omachi TA, Chang E, Luskin A. Corticosteroid-related toxicity in patients with chronic idiopathic urticariachronic spontaneous urticaria. Allergy Asthma Proc. 2016;37(6):458\u201365. https:\/\/doi.org\/10.2500\/aap.2016.37.3999.","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"902_CR27","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.clindermatol.2006.07.007","volume":"24","author":"JA Carlson","year":"2006","unstructured":"Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol. 2006;24(5):414\u201329. https:\/\/doi.org\/10.1016\/j.clindermatol.2006.07.007.","journal-title":"Clin Dermatol"},{"issue":"3","key":"902_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijwd.2021.01.021","volume":"7","author":"SL Gu","year":"2021","unstructured":"Gu SL, Jorizzo JL. Urticarial vasculitis. Int J Womens Dermatol. 2021;7(3):290\u20137. https:\/\/doi.org\/10.1016\/j.ijwd.2021.01.021.","journal-title":"Int J Womens Dermatol."},{"issue":"2","key":"902_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","volume":"6","author":"K Kulthanan","year":"2018","unstructured":"Kulthanan K, Chaweekulrat P, Komoltri C, Hunnangkul S, Tuchinda P, Chularojanamontri L, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586\u201399. https:\/\/doi.org\/10.1016\/j.jaip.2017.07.017.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"902_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2133.2009.09538.x","volume":"162","author":"A Perez","year":"2010","unstructured":"Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol. 2010;162(1):191\u20134. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09538.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"902_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/14782715221144167","volume":"53","author":"C Teles","year":"2023","unstructured":"Teles C, Gaspar E, Gon\u00e7alo M, Santos L. Normocomplementemic urticarial vasculitis secondary to Lyme disease: a rare association with challenging treatment. J R Coll Physicians Edinb. 2023;53(1):27\u20139. https:\/\/doi.org\/10.1177\/14782715221144167.","journal-title":"J R Coll Physicians Edinb"},{"issue":"1","key":"902_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1365-2133.2000.03624.x","volume":"143","author":"A Borcea","year":"2000","unstructured":"Borcea A, Greaves MW. Methotrexate-induced exacerbation of urticarial vasculitis: an unusual adverse reaction. Br J Dermatol. 2000;143(1):203\u20134. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03624.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"902_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13256-022-03477-6","volume":"16","author":"K Smets","year":"2022","unstructured":"Smets K, Van Baelen A, Sprangers B, De Haes P. Correct approach in urticarial vasculitis made early diagnosis of lupus nephritis possible: a case report. J Med Case Rep. 2022;16(1):314. https:\/\/doi.org\/10.1186\/s13256-022-03477-6.","journal-title":"J Med Case Rep"},{"issue":"11","key":"902_CR34","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1007\/s00296-010-1484-4","volume":"32","author":"PA Mac\u00eado","year":"2012","unstructured":"Mac\u00eado PA, Garcia CB, Schmitz MK, Jales LH, Pereira RMR, Carvalho JF. Juvenile systemic lupus erythematosus and dermatomyositis associated with urticarial vasculitis syndrome: a unique presentation. Rheumatol Int. 2012;32(11):3643\u20136. https:\/\/doi.org\/10.1007\/s00296-010-1484-4.","journal-title":"Rheumatol Int"},{"issue":"5","key":"902_CR35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10875-013-9886-1","volume":"33","author":"L Breda","year":"2013","unstructured":"Breda L, Nozzi M, Harari S, Del Torto M, Lucantoni M, Scardapane A, et al. Hypocomplementemic urticarial vasculitis (HUVS) with precocious emphysema responsive to azathioprine. J Clin Immunol. 2013;33(5):891\u20135. https:\/\/doi.org\/10.1007\/s10875-013-9886-1.","journal-title":"J Clin Immunol"},{"issue":"2","key":"902_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1385\/CRIAI:23:2:201","volume":"23","author":"J Venzor","year":"2002","unstructured":"Venzor J, Lee WL, Huston DP. Urticarial vasculitis. Clin Rev Allergy Immunol. 2002;23(2):201\u201316. https:\/\/doi.org\/10.1385\/CRIAI:23:2:201.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"902_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jns.2009.03.027","volume":"284","author":"M Filosto","year":"2009","unstructured":"Filosto M, Cavallaro T, Pasolini G, Broglio L, Tentorio M, Cotelli M, et al. Idiopathic hypocomplementemic urticarial vasculitis-linked neuropathy. J Neurol Sci. 2009;284(1):179\u201381. https:\/\/doi.org\/10.1016\/j.jns.2009.03.027.","journal-title":"J Neurol Sci"},{"issue":"4","key":"902_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2230.1995.tb01343.x","volume":"20","author":"SR Knowles","year":"1995","unstructured":"Knowles SR, Gupta AK, Shear NH, Sauder D. Azathioprine hypersensitivity-like reactions: a case report and a review of the literature. Clin Exp Dermatol. 1995;20(4):353\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1995.tb01343.x.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"902_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12882-020-02001-6","volume":"21","author":"K Vallianou","year":"2020","unstructured":"Vallianou K, Skalioti C, Liapis G, Boletis JN, Marinaki S. A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis. BMC Nephrol. 2020;21(1):351. https:\/\/doi.org\/10.1186\/s12882-020-02001-6.","journal-title":"BMC Nephrol"},{"issue":"4","key":"902_CR40","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1046\/j.1365-2133.1998.02473.x","volume":"139","author":"M Worm","year":"1998","unstructured":"Worm M, Muche M, Schulze P, Sterry W, Kolde G. Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. Br J Dermatol. 1998;139(4):704\u20137. https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02473.x.","journal-title":"Br J Dermatol"},{"key":"902_CR41","volume-title":"Cyclophosphamide","author":"MH Ogino","year":"2024","unstructured":"Ogino MH, Tadi P. Cyclophosphamide. Treasure Island: StatPearls Publishing LLC; 2024."},{"issue":"4","key":"902_CR42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaip.2018.05.006","volume":"6","author":"MDP Davis","year":"2018","unstructured":"Davis MDP, van der Hilst JCH. Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases. J Allergy Clin Immunol Pract. 2018;6(4):1162\u201370. https:\/\/doi.org\/10.1016\/j.jaip.2018.05.006.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"902_CR43","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1046\/j.1365-2133.2000.03913.x","volume":"143","author":"M Worm","year":"2000","unstructured":"Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol. 2000;143(6):1324. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03913.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"902_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2340\/00015555-1909","volume":"95","author":"J Christiansen","year":"2015","unstructured":"Christiansen J, Kahn R, Schmidtchen A, Bergg\u00e5rd K. Idiopathic angioedema and urticarial vasculitis in a patient with a history of acquired haemophilia. Acta Derm Venereol. 2015;95(2):227\u20138. https:\/\/doi.org\/10.2340\/00015555-1909.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"902_CR45","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1046\/j.1365-2230.2003.01336.x","volume":"28","author":"KS Leslie","year":"2003","unstructured":"Leslie KS, Gaffney K, Ross CN, Ridley S, Barker TH, Garioch JJ. A near fatal case of the dapsone hypersensitivity syndrome in a patient with urticarial vasculitis. Clin Exp Dermatol. 2003;28(5):496\u20138. https:\/\/doi.org\/10.1046\/j.1365-2230.2003.01336.x.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"902_CR46","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1111\/j.1365-2230.2009.03527.x","volume":"34","author":"JS Chun","year":"2009","unstructured":"Chun JS, Yun SJ, Kim SJ, Lee SC, Won YH, Lee JB. Dapsone hypersensitivity syndrome with circulating 190-kDa and 230-kDa autoantibodies. Clin Exp Dermatol. 2009;34(8):e798-801. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03527.x.","journal-title":"Clin Exp Dermatol"},{"issue":"3 Pt 2","key":"902_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/0190-9622(92)70069-r","volume":"26","author":"DR Mehregan","year":"1992","unstructured":"Mehregan DR, Hall MJ, Gibson LE. Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol. 1992;26(3 Pt 2):441\u20138. https:\/\/doi.org\/10.1016\/0190-9622(92)70069-r.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"902_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00005792-199501000-00003","volume":"74","author":"JJ Wisnieski","year":"1995","unstructured":"Wisnieski JJ, Baer AN, Christensen J, Cupps TR, Flagg DN, Jones JV, et al. Hypocomplementemic urticarial vasculitis syndrome: clinical and serologic findings in 18 patients. Medicine (Baltimore). 1995;74(1):24\u201341. https:\/\/doi.org\/10.1097\/00005792-199501000-00003.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"902_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14531","volume":"33","author":"E Bostan","year":"2020","unstructured":"Bostan E, Akdogan N, Gokoz O, Dogan S. Rapid response to combination of hydroxychloroquine and prednisolone in a patient with refractory hypocomplementemic urticarial vasculitis. Dermatol Ther. 2020;33(6): e14531. https:\/\/doi.org\/10.1111\/dth.14531.","journal-title":"Dermatol Ther"},{"issue":"2","key":"902_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.nephro.2019.09.004","volume":"16","author":"A Boyer","year":"2020","unstructured":"Boyer A, Gautier N, Comoz F, Hurault de Ligny B, Aouba A, Lanot A. N\u00e9phropathie associ\u00e9e \u00e0 une vascularite urticarienne hypocompl\u00e9ment\u00e9mique: pr\u00e9sentation d\u2019un cas clinique et revue de la litt\u00e9rature. Nephrol Ther. 2020;16(2):124\u201335. https:\/\/doi.org\/10.1016\/j.nephro.2019.09.004.","journal-title":"Nephrol Ther"},{"issue":"3","key":"902_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2340\/00015555-0249","volume":"87","author":"C Prins","year":"2007","unstructured":"Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3):206\u201318. https:\/\/doi.org\/10.2340\/00015555-0249.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"902_CR52","doi-asserted-by":"publisher","first-page":"513","DOI":"10.14744\/nci.2020.55476","volume":"8","author":"G Serarslan","year":"2021","unstructured":"Serarslan G, Okyay E. Clinical characteristics and treatment outcomes in patients with urticarial vasculitis. North Clin Istanb. 2021;8(5):513\u20137. https:\/\/doi.org\/10.14744\/nci.2020.55476.","journal-title":"North Clin Istanb."},{"issue":"2","key":"902_CR53","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/1346-8138.15712","volume":"48","author":"M Fujii","year":"2021","unstructured":"Fujii M, Kishibe M, Ishida-Yamamoto A. Case of hypocomplementemic urticarial vasculitis with Sj\u00f6gren\u2019s syndrome successfully treated with oral corticosteroid and colchicine. J Dermatol. 2021;48(2):e112\u20133. https:\/\/doi.org\/10.1111\/1346-8138.15712.","journal-title":"J Dermatol"},{"issue":"2","key":"902_CR54","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1365-2133.2008.08990.x","volume":"160","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Misbah S, Wilkinson J, Wordsworth P. Refractory urticarial vasculitis responsive to anti-B-cell therapy. Br J Dermatol. 2009;160(2):470\u20132. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08990.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"902_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0049-0172(91)90029-y","volume":"20","author":"RA Asherson","year":"1991","unstructured":"Asherson RA, D\u2019Cruz D, Stephens CJ, McKee PH, Hughes GR. Urticarial vasculitis in a connective tissue disease clinic: patterns, presentations, and treatment. Semin Arthritis Rheum. 1991;20(5):285\u201396. https:\/\/doi.org\/10.1016\/0049-0172(91)90029-y.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"902_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2230.1992.tb00183.x","volume":"17","author":"RA Asherson","year":"1992","unstructured":"Asherson RA, Buchanan NM, d\u2019Cruz D, Hughes GR. Urticarial vasculitis, IgA deficiency and C1 esterase inhibitor deficiency in the presence of an IgG monoclonal gammopathy: a case report. Clin Exp Dermatol. 1992;17(2):137\u20139. https:\/\/doi.org\/10.1111\/j.1365-2230.1992.tb00183.x.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"902_CR57","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/j.1398-9995.2006.01231.x","volume":"61","author":"GI Athanasiadis","year":"2006","unstructured":"Athanasiadis GI, Pfab F, Kollmar A, Ring J, Ollert M. Urticarial vasculitis with a positive autologous serum skin test: diagnosis and successful therapy. Allergy. 2006;61(12):1484\u20135. https:\/\/doi.org\/10.1111\/j.1398-9995.2006.01231.x.","journal-title":"Allergy"},{"issue":"4","key":"902_CR58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11926-007-0050-x","volume":"9","author":"NA Brown","year":"2007","unstructured":"Brown NA, Carter JD. Urticarial vasculitis. Curr Rheumatol Rep. 2007;9(4):312\u20139. https:\/\/doi.org\/10.1007\/s11926-007-0050-x.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"902_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/QAD.0b013e328011cb38","volume":"21","author":"MC Lipman","year":"2007","unstructured":"Lipman MC, Carding SK. Successful drug treatment of immune reconstitution disease with the leukotriene receptor antagonist, montelukast: a clue to pathogenesis? AIDS. 2007;21(3):383\u20134. https:\/\/doi.org\/10.1097\/QAD.0b013e328011cb38.","journal-title":"AIDS"},{"issue":"1","key":"902_CR60","first-page":"49","volume":"81","author":"PE Koch","year":"2008","unstructured":"Koch PE, Lazova R, Rosen JR, Antaya RJ. Urticarial vasculitis in an infant. Cutis. 2008;81(1):49\u201352.","journal-title":"Cutis"},{"issue":"6","key":"902_CR61","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/archdermatol.2009.13","volume":"145","author":"M Morgan","year":"2009","unstructured":"Morgan M. Treatment of refractory chronic urticaria with sirolimus. Arch Dermatol. 2009;145(6):637\u20139. https:\/\/doi.org\/10.1001\/archdermatol.2009.13.","journal-title":"Arch Dermatol"},{"issue":"1","key":"902_CR62","first-page":"36","volume":"5","author":"A Buck","year":"2012","unstructured":"Buck A, Christensen J, McCarty M. Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review. J Clin Aesthet Dermatol. 2012;5(1):36\u201346.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4","key":"902_CR63","doi-asserted-by":"publisher","first-page":"503","DOI":"10.7705\/biomedica.v33i4.782","volume":"33","author":"LS D\u00edez","year":"2013","unstructured":"D\u00edez LS, Tamayo LM, Cardona R. Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases. Biomedica. 2013;33(4):503\u201312. https:\/\/doi.org\/10.7705\/biomedica.v33i4.782.","journal-title":"Biomedica"},{"issue":"4","key":"902_CR64","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/ced.13076","volume":"42","author":"A Fueyo-Casado","year":"2017","unstructured":"Fueyo-Casado A, Campos-Mu\u00f1oz L, Gonz\u00e1lez-Guerra E, Pedraz-Mu\u00f1oz J, Cort\u00e9s-Toro JA, L\u00f3pez-Bran E. Effectiveness of omalizumab in a case of urticarial vasculitis. Clin Exp Dermatol. 2017;42(4):403\u20135. https:\/\/doi.org\/10.1111\/ced.13076.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"902_CR65","first-page":"321","volume":"69","author":"JPC Garc\u0131a Ponce","year":"2014","unstructured":"Garc\u0131a Ponce JPC, Jimenez Timon S, Maghfour Martin Y, Ahmida T, Hernandez Arbeiza FJ. Urticarial vasculitis (leucocytoclastic vasculitis) treated with omalizumab: case report. Allergy. 2014;69(3):321.","journal-title":"Allergy"},{"issue":"6","key":"902_CR66","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu AWL, Wong MM, Rayner DG, Guyatt GH, D\u00edaz Martinez JP, Ceccacci R, et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470\u201392. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"902_CR67","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/all.12901","volume":"71","author":"M Maurer","year":"2016","unstructured":"Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, et al. Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. Allergy. 2016;71(8):1210\u20138. https:\/\/doi.org\/10.1111\/all.12901.","journal-title":"Allergy"},{"issue":"2","key":"902_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12031","volume":"11","author":"V Puhl","year":"2021","unstructured":"Puhl V, Bonnekoh H, Scheffel J, Hawro T, Weller K, von den Driesch P, et al. A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. Clin Transl Allergy. 2021;11(2): e12031. https:\/\/doi.org\/10.1002\/clt2.12031.","journal-title":"Clin Transl Allergy."},{"key":"902_CR69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5414\/alx02375e","volume":"7","author":"H Bonnekoh","year":"2023","unstructured":"Bonnekoh H, Krause K, Kolkhir P. Chronic recurrent wheals: if not chronic spontaneous urticaria, what else? Allergol Select. 2023;7:8\u201316. https:\/\/doi.org\/10.5414\/alx02375e.","journal-title":"Allergol Select."},{"issue":"2","key":"902_CR70","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jaip.2022.11.016","volume":"11","author":"P Kolkhir","year":"2023","unstructured":"Kolkhir P, Laires PA, Salameh P, Asero R, Bizjak M, Ko\u0161nik M, et al. The benefit of complete response to treatment in patients with chronic spontaneous urticaria: CURE results. J Allergy Clin Immunol Pract. 2023;11(2):610-20.e5. https:\/\/doi.org\/10.1016\/j.jaip.2022.11.016.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"902_CR71","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","volume":"18","author":"JA Bernstein","year":"2018","unstructured":"Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald K, Denhaerynck K, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u201creal-world\u201d evidence. Expert Opin Biol Ther. 2018;18(4):425\u201348. https:\/\/doi.org\/10.1080\/14712598.2018.1438406.","journal-title":"Expert Opin Biol Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00902-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00902-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00902-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:48:43Z","timestamp":1737082123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00902-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["902"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00902-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"7 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nikolai Dario Rothermel, Carolina Vera Ayala, Leonie Shirin Herzog, Polina Pyatilova, and Sophia Neisinger have no conflicts of interest that are directly relevant to the content of this article. Emek Kocat\u00fcrk was a speaker\/consultant and\/or advisor for and\/or has received research funding from Novartis, Menarini, LaRoche Posey, Sanofi, Bayer, Abdi \u0130brahim, and Pfizer outside of the submitted work. Indrashis Podder has no conflicts of interest to declare in relation to the current work. Outside of it, he is or recently was a speaker and\/or advisor for Menarini, Sun Pharmaceuticals, Glenmark, Cipla, and Alkem Laboratories. Jie Shen Fok has previously received speaker honorarium or\/and travel sponsorship from CSL Behring, Menarini, Viatris, Takeda, and Novartis outside of submitted work. Manuel P. Pereira has received research funding from Almirall and Pfizer; is an investigator for Allakos, Celldex Therapeutics, Incyte, Sanofi, and Trevi Therapeutics; and has received consulting fees, speaker honoraria and\/or travel fees from AbbVie, Beiersdorf, Celltrion, Doctorflix, Eli Lilly, GA2LEN, Galderma, Menlo Therapeutics, Novartis, P.G. Unna Academy, Sanofi, Streamed UP, and Trevi Therapeutics. Margarida Gon\u00e7alo is or has been advisor and\/or received fees for lectures from AbbVie, Astra-Zeneca, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi, and Takeda outside of the submitted work. Melba Munoz is or recently was, outside of the submitted work, a speaker and\/or advisor for and\/or has received research funding from Jasper Therapeutics, Celldex Therapeutics, Takeda, GA\n                      2\n                      LEN, UNEV, Astra Zeneca, and Roche. Karoline Krause has no conflict of interest related to this work. Outside of it, she received research funding and or honoraria from Bayer, Beiersdorf, Berlin Chemie, CSL Behring, Moxie, Novartis, Roche\/CHUGAI, Sobi, and Takeda. Marcus Maurer is or recently was, outside of the submitted work, a speaker and\/or advisor for and\/or has received research funding from Allakos, Alexion, Alvotech, Almirall, Amgen, Aquestive, argenX, AstraZeneca, Celldex, Celltrion, Clinuvel, Escient, Evommune, Excellergy, GSK, Incyte, Jasper, Kashiv, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Resoncance Medicine, Sanofi\/Regeneron, Santa Ana Bio, Septerna, Servier, Third HarmonicBio, ValenzaBio, Vitalli Bio, Yuhan Corporation, and Zurabio. Hanna Bonnekoh was a speaker\/consultant and\/or advisor for and\/or has received research funding AbbVie, Novartis, Sanofi Aventis, and ValenzaBio outside of the submitted work. Pavel Kolkhir was a speaker\/consultant and\/or advisor for and\/or has received research funding from Novartis, ValenzaBio, and Roche outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This is a review article and does not involve human subjects, therefore no primary data were used. Data from studies presented in this article are summarized in the tables and supplementary tables.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"NR, HB, and PK contributed to the conceptualization, methodology, data curation, and writing (original draft). AR, CVA, EK, IP, JF, LH, MP, MG, MMu, PP, and SN contributed to the methodology, data curation, and writing (original draft). MM and KK contributed to data curation and writing (review and editing). All authors contributed to the consensus process that led to this article, reviewed the literature, critically reviewed and revised the article, and proofread and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}